Leadman(SZ:300289)2025-01-22 09:02Financial Performance Expectations - The company expects a net loss attributable to shareholders of between 67 million and 77 million RMB for the year 2024, compared to a profit of 15.34 million RMB in the same period last year[3]. - The projected net loss after deducting non-recurring gains and losses is estimated to be between 89 million and 99 million RMB, down from a profit of 8.79 million RMB in the previous year[3]. - Total operating revenue is expected to be between 365 million and 375 million RMB, a decrease from 461.55 million RMB in the prior year[3]. Non-Recurring Gains and Losses - The expected impact of non-recurring gains and losses on net profit is approximately 22 million RMB, primarily from government subsidies and investment income[5][6]. Revenue and Profit Margin Adjustments - The company has adjusted the sales prices of certain diagnostic reagent products, leading to a decline in both revenue and gross profit margins[5]. Goodwill Impairment Assessment - The company plans to assess goodwill impairment for subsidiaries that are not meeting performance expectations, with the final impairment amount to be determined by professional evaluation and audit[5]. Caution for Investors - The financial data in the earnings forecast is based on preliminary calculations by the company's finance department and has not yet been audited[7]. - The company emphasizes the importance of cautious decision-making for investors due to the anticipated financial performance[7].